prs_id	slug	legacy_id	legacy_model	prswebprefix	trait_code	trait_name	trait_type	description	cohort	cohort_label	method	gwas_source	reference_label	reference_url	snp_count	p_value	pseudo_r2	brier_score	mse	aauc	aauc_ci	effect_metric	top_effect_1	top_effect_1_ci	top_or_1	top_or_1_ci	top_effect_2	top_effect_2_ci	top_or_2	top_or_2_ci	top_effect_5	top_effect_5_ci	top_or_5	top_or_5_ci	top_effect_10	top_effect_10_ci	top_or_10	top_or_10_ci	top_effect_25	top_effect_25_ci	top_or_25	top_or_25_ci	q1_vs_q2_effect	q1_vs_q2_effect_ci	q1_vs_q2_p_value	q1_vs_q3_effect	q1_vs_q3_effect_ci	q1_vs_q3_p_value	q1_vs_q4_effect	q1_vs_q4_effect_ci	q1_vs_q4_p_value	nominally_significant	reversed_effect_warning	underpowered_warning	upload_to_portal	sex	cases	controls	genome_build	tuning_parameter	weights_external_url	weights_url	phewas_download_url	exclusion_download_url	last_updated
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-05-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-05_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-05)	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	105	2.3e-125	0.0211669	0.0821		0.586	0.579-0.594	OR	2.24	1.86-2.7	2.24	1.86-2.7	2.08	1.81-2.39	2.08	1.81-2.39	1.92	1.75-2.11	1.92	1.75-2.11	1.8	1.68-1.93	1.8	1.68-1.93	1.72	1.63-1.82	1.72	1.63-1.82	1.31	1.2-1.42	5.02e-10	1.57	1.44-1.7	3.22e-27	2.23	2.06-2.41	1.6e-92	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	392	1.2e-57	0.0084719	0.0825		0.559	0.551-0.566	OR	1.75	1.42-2.15	1.75	1.42-2.15	1.64	1.41-1.91	1.64	1.41-1.91	1.6	1.44-1.76	1.6	1.44-1.76	1.57	1.46-1.7	1.57	1.46-1.7	1.46	1.38-1.54	1.46	1.38-1.54	1.14	1.06-1.24	0.000916	1.3	1.2-1.41	3.61e-11	1.68	1.56-1.81	1.82e-42	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	950	6.4e-226	0.0384878	0.0814		0.617	0.61-0.625	OR	3.47	2.96-4.06	3.47	2.96-4.06	2.83	2.51-3.2	2.83	2.51-3.2	2.49	2.29-2.72	2.49	2.29-2.72	2.22	2.07-2.37	2.22	2.07-2.37	2.07	1.96-2.18	2.07	1.96-2.18	1.4	1.28-1.54	1.13e-13	1.83	1.68-2	4.73e-44	2.92	2.7-3.17	4.11e-152	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1307	7.1e-265	0.0443191	0.0812		0.627	0.62-0.634	OR	3.49	2.98-4.08	3.49	2.98-4.08	3.14	2.78-3.53	3.14	2.78-3.53	2.68	2.46-2.91	2.68	2.46-2.91	2.34	2.19-2.5	2.34	2.19-2.5	2.18	2.07-2.3	2.18	2.07-2.3	1.51	1.37-1.65	1.43e-18	1.92	1.76-2.1	8e-49	3.22	2.97-3.49	1.86e-173	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	158	3.1e-12	0.00204393	0.0827		0.526	0.518-0.533	OR	1.21	0.952-1.54	1.21	0.952-1.54	1.28	1.09-1.52	1.28	1.09-1.52	1.21	1.09-1.35	1.21	1.09-1.35	1.18	1.09-1.28	1.18	1.09-1.28	1.12	1.05-1.18	1.12	1.05-1.18	1.04	0.965-1.13	0.294	1.22	1.13-1.32	1.14e-07	1.22	1.13-1.31	2.49e-07	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	423	1.5e-150	0.0235116	0.0819		0.596	0.589-0.603	OR	2.49	2.08-2.98	2.49	2.08-2.98	2.21	1.93-2.53	2.21	1.93-2.53	2.12	1.94-2.32	2.12	1.94-2.32	1.93	1.8-2.07	1.93	1.8-2.07	1.81	1.71-1.91	1.81	1.71-1.91	1.3	1.2-1.42	1.45e-09	1.66	1.53-1.8	9.02e-34	2.39	2.21-2.58	8.46e-107	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-icogs-overall-brca-p-5e-05-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-p-5e-05-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-05_UKB_20200608	P_5e-05	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-05_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-05)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	534	3e-162	0.0258641	0.0818		0.6	0.593-0.608	OR	2.86	2.41-3.39	2.86	2.41-3.39	2.58	2.27-2.93	2.58	2.27-2.93	2.08	1.9-2.28	2.08	1.9-2.28	1.96	1.83-2.1	1.96	1.83-2.1	1.8	1.7-1.9	1.8	1.7-1.9	1.33	1.22-1.45	2.08e-10	1.76	1.62-1.92	1.5e-41	2.45	2.27-2.65	3.84e-111	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-06-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-06_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-06)	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	102	6.3e-132	0.0230285	0.082		0.589	0.582-0.597	OR	2.26	1.88-2.72	2.26	1.88-2.72	2.08	1.81-2.39	2.08	1.81-2.39	1.97	1.8-2.16	1.97	1.8-2.16	1.83	1.71-1.97	1.83	1.71-1.97	1.74	1.64-1.83	1.74	1.64-1.83	1.38	1.27-1.51	7.66e-14	1.65	1.52-1.79	1.26e-32	2.34	2.16-2.53	6.94e-101	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	133	2.5e-64	0.0083826	0.0824		0.561	0.553-0.568	OR	1.81	1.48-2.22	1.81	1.48-2.22	1.82	1.57-2.1	1.82	1.57-2.1	1.67	1.51-1.84	1.67	1.51-1.84	1.48	1.37-1.6	1.48	1.37-1.6	1.38	1.31-1.46	1.38	1.31-1.46	1.2	1.11-1.3	8.03e-06	1.49	1.38-1.61	8.1e-24	1.7	1.58-1.84	4.49e-43	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	495	2.2e-225	0.0389156	0.0814		0.617	0.61-0.625	OR	3.06	2.6-3.61	3.06	2.6-3.61	2.74	2.42-3.11	2.74	2.42-3.11	2.45	2.25-2.67	2.45	2.25-2.67	2.27	2.12-2.43	2.27	2.12-2.43	2.05	1.94-2.16	2.05	1.94-2.16	1.45	1.33-1.59	3.4e-16	1.89	1.73-2.06	9.02e-48	2.97	2.74-3.22	3.56e-154	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	712	1.5e-271	0.0437374	0.0811		0.628	0.62-0.635	OR	3.69	3.16-4.31	3.69	3.16-4.31	3.16	2.81-3.56	3.16	2.81-3.56	2.71	2.49-2.94	2.71	2.49-2.94	2.41	2.26-2.58	2.41	2.26-2.58	2.13	2.02-2.25	2.13	2.02-2.25	1.61	1.46-1.76	8.15e-24	2.09	1.92-2.29	1.8e-60	3.34	3.07-3.63	1.99e-177	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	35	8.5e-28	0.00333191	0.0826		0.537	0.53-0.545	OR	1.39	1.11-1.74	1.39	1.11-1.74	1.51	1.29-1.76	1.51	1.29-1.76	1.42	1.28-1.57	1.42	1.28-1.57	1.33	1.23-1.43	1.33	1.23-1.43	1.27	1.2-1.34	1.27	1.2-1.34	1.16	1.07-1.25	0.000258	1.29	1.2-1.4	4.24e-11	1.46	1.35-1.57	3.81e-23	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	185	6.6e-168	0.0285405	0.0818		0.6	0.593-0.608	OR	2.74	2.31-3.26	2.74	2.31-3.26	2.41	2.11-2.74	2.41	2.11-2.74	2.04	1.86-2.23	2.04	1.86-2.23	1.92	1.79-2.06	1.92	1.79-2.06	1.93	1.83-2.04	1.93	1.83-2.04	1.41	1.29-1.54	8.62e-15	1.66	1.53-1.81	2.64e-32	2.63	2.43-2.84	6.7e-128	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-icogs-overall-brca-p-5e-06-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-p-5e-06-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-06_UKB_20200608	P_5e-06	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-06_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-06)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	246	4.1e-175	0.0291108	0.0817		0.603	0.595-0.61	OR	2.87	2.43-3.4	2.87	2.43-3.4	2.46	2.16-2.8	2.46	2.16-2.8	2.29	2.1-2.5	2.29	2.1-2.5	2.01	1.88-2.15	2.01	1.88-2.15	1.9	1.8-2.01	1.9	1.8-2.01	1.34	1.23-1.47	3.38e-11	1.72	1.58-1.87	3.13e-37	2.58	2.39-2.79	1.02e-123	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-07-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-07_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-07)	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	93	1.7e-144	0.0248677	0.0819		0.594	0.586-0.601	OR	2.58	2.16-3.08	2.58	2.16-3.08	2.34	2.05-2.67	2.34	2.05-2.67	2.05	1.87-2.25	2.05	1.87-2.25	1.91	1.78-2.05	1.91	1.78-2.05	1.74	1.64-1.83	1.74	1.64-1.83	1.44	1.32-1.56	1.87e-16	1.76	1.62-1.92	5.22e-41	2.43	2.25-2.63	2.01e-107	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	73	7.7e-61	0.00809412	0.0824		0.56	0.552-0.567	OR	1.76	1.44-2.16	1.76	1.44-2.16	1.95	1.7-2.25	1.95	1.7-2.25	1.65	1.49-1.82	1.65	1.49-1.82	1.49	1.38-1.61	1.49	1.38-1.61	1.43	1.35-1.51	1.43	1.35-1.51	1.17	1.08-1.26	0.000188	1.41	1.3-1.52	5.14e-18	1.7	1.58-1.83	1.34e-43	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	343	3.1e-218	0.0375986	0.0815		0.615	0.607-0.622	OR	3.01	2.55-3.56	3.01	2.55-3.56	2.86	2.53-3.23	2.86	2.53-3.23	2.38	2.18-2.6	2.38	2.18-2.6	2.19	2.05-2.35	2.19	2.05-2.35	2.02	1.91-2.13	2.02	1.91-2.13	1.44	1.31-1.57	1.65e-15	1.84	1.69-2.01	1.12e-44	2.88	2.66-3.12	1.5e-147	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	464	2.3e-260	0.0434102	0.0812		0.626	0.618-0.633	OR	3.81	3.27-4.44	3.81	3.27-4.44	3.19	2.83-3.59	3.19	2.83-3.59	2.53	2.33-2.76	2.53	2.33-2.76	2.4	2.24-2.56	2.4	2.24-2.56	2.14	2.03-2.26	2.14	2.03-2.26	1.55	1.41-1.7	6.18e-21	1.98	1.82-2.16	7.21e-53	3.23	2.98-3.51	1.65e-172	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	14	2.2e-44	0.00581917	0.0825		0.547	0.54-0.555	OR	1.73	1.41-2.13	1.73	1.41-2.13	1.63	1.4-1.89	1.63	1.4-1.89	1.51	1.36-1.67	1.51	1.36-1.67	1.39	1.29-1.5	1.39	1.29-1.5	1.38	1.3-1.46	1.38	1.3-1.46	1.2	1.1-1.29	1.11e-05	1.35	1.25-1.46	6.02e-14	1.63	1.51-1.76	3.48e-37	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	113	2.7e-162	0.027191	0.0818		0.597	0.59-0.604	OR	2.71	2.28-3.22	2.71	2.28-3.22	2.46	2.16-2.8	2.46	2.16-2.8	2.1	1.92-2.3	2.1	1.92-2.3	1.97	1.83-2.11	1.97	1.83-2.11	1.82	1.72-1.92	1.82	1.72-1.92	1.34	1.23-1.46	5.84e-11	1.74	1.61-1.89	1.13e-39	2.48	2.29-2.68	6.35e-114	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-icogs-overall-brca-p-5e-07-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-p-5e-07-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-07_UKB_20200608	P_5e-07	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-07_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-07)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	154	6.6e-176	0.0295653	0.0818		0.603	0.595-0.61	OR	2.65	2.22-3.15	2.65	2.22-3.15	2.27	1.99-2.6	2.27	1.99-2.6	2.19	2-2.39	2.19	2-2.39	1.99	1.85-2.13	1.99	1.85-2.13	1.94	1.84-2.04	1.94	1.84-2.04	1.3	1.19-1.42	3.12e-09	1.67	1.54-1.82	1.25e-33	2.57	2.38-2.78	3.55e-124	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-09-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-09_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	Fixed threshold (5e-09)	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	64	1.2e-146	0.0254827	0.0819		0.595	0.588-0.602	OR	2.44	2.04-2.92	2.44	2.04-2.92	2.33	2.04-2.66	2.33	2.04-2.66	2.1	1.92-2.3	2.1	1.92-2.3	1.93	1.8-2.07	1.93	1.8-2.07	1.79	1.69-1.89	1.79	1.69-1.89	1.33	1.22-1.45	4.62e-11	1.69	1.55-1.83	1.18e-35	2.39	2.21-2.59	1.66e-106	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	31	1.3e-56	0.00782901	0.0825		0.556	0.548-0.564	OR	1.95	1.6-2.37	1.95	1.6-2.37	1.8	1.56-2.08	1.8	1.56-2.08	1.73	1.57-1.9	1.73	1.57-1.9	1.53	1.42-1.65	1.53	1.42-1.65	1.44	1.36-1.52	1.44	1.36-1.52	1.22	1.12-1.32	1.49e-06	1.33	1.23-1.44	1.46e-12	1.7	1.58-1.83	1.08e-43	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	210	1.6e-200	0.0339286	0.0816		0.61	0.603-0.617	OR	2.7	2.27-3.21	2.7	2.27-3.21	2.53	2.23-2.87	2.53	2.23-2.87	2.35	2.16-2.57	2.35	2.16-2.57	2.17	2.03-2.33	2.17	2.03-2.33	1.99	1.89-2.1	1.99	1.89-2.1	1.36	1.25-1.49	7.17e-12	1.79	1.64-1.95	1.57e-41	2.75	2.54-2.98	1.76e-138	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	264	1.4e-236	0.0390059	0.0813		0.62	0.612-0.627	OR	3.28	2.79-3.86	3.28	2.79-3.86	2.92	2.59-3.3	2.92	2.59-3.3	2.57	2.36-2.79	2.57	2.36-2.79	2.28	2.14-2.44	2.28	2.14-2.44	2.09	1.98-2.21	2.09	1.98-2.21	1.44	1.31-1.57	2.77e-15	1.89	1.73-2.06	1.73e-47	3.02	2.78-3.27	1.49e-158	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	8	5e-31	0.00425293	0.0826		0.536	0.528-0.544	OR	1.77	1.44-2.17	1.77	1.44-2.17	1.57	1.35-1.83	1.57	1.35-1.83	1.31	1.18-1.46	1.31	1.18-1.46	1.26	1.16-1.37	1.26	1.16-1.37	1.32	1.25-1.4	1.32	1.25-1.4	1.19	1.1-1.28	1.75e-05	1.25	1.16-1.35	1.21e-08	1.52	1.41-1.63	4.77e-28	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	63	6e-150	0.0272888	0.0819		0.593	0.586-0.6	OR	2.76	2.33-3.28	2.76	2.33-3.28	2.31	2.02-2.63	2.31	2.02-2.63	2.04	1.86-2.24	2.04	1.86-2.24	1.95	1.82-2.09	1.95	1.82-2.09	1.79	1.69-1.89	1.79	1.69-1.89	1.31	1.2-1.42	1.13e-09	1.67	1.54-1.81	2.33e-34	2.37	2.19-2.56	1.89e-104	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-icogs-overall-brca-p-5e-09-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-p-5e-09-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-09_UKB_20200608	P_5e-09	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-09_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	Fixed threshold (5e-09)	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	77	2e-168	0.0298674	0.0818		0.6	0.593-0.607	OR	2.58	2.16-3.08	2.58	2.16-3.08	2.4	2.11-2.74	2.4	2.11-2.74	2.13	1.94-2.33	2.13	1.94-2.33	1.99	1.86-2.13	1.99	1.86-2.13	1.86	1.77-1.97	1.86	1.77-1.97	1.26	1.16-1.38	1.72e-07	1.71	1.57-1.85	2.63e-37	2.47	2.28-2.67	1.92e-114	True	False	False	False	Female	6242	62289	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-08-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	GWAS Hits	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	86	3.9e-139	0.0244675	0.082		0.592	0.585-0.6	OR	2.58	2.16-3.07	2.58	2.16-3.07	2.37	2.08-2.7	2.37	2.08-2.7	2.04	1.87-2.24	2.04	1.87-2.24	1.85	1.72-1.98	1.85	1.72-1.98	1.72	1.63-1.82	1.72	1.63-1.82	1.42	1.3-1.54	1.99e-15	1.76	1.62-1.91	6.72e-41	2.4	2.22-2.59	1.05e-104	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	49	8.9e-63	0.00912193	0.0824		0.559	0.551-0.566	OR	2.03	1.67-2.46	2.03	1.67-2.46	1.98	1.72-2.28	1.98	1.72-2.28	1.63	1.48-1.8	1.63	1.48-1.8	1.59	1.47-1.71	1.59	1.47-1.71	1.45	1.38-1.54	1.45	1.38-1.54	1.26	1.16-1.36	2.24e-08	1.37	1.27-1.49	3.23e-15	1.76	1.63-1.9	7.25e-49	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	257	1.8e-212	0.0361392	0.0815		0.613	0.606-0.621	OR	2.71	2.28-3.23	2.71	2.28-3.23	2.61	2.3-2.96	2.61	2.3-2.96	2.41	2.21-2.63	2.41	2.21-2.63	2.25	2.1-2.41	2.25	2.1-2.41	2	1.9-2.11	2	1.9-2.11	1.43	1.31-1.57	2.45e-15	1.87	1.72-2.03	7.66e-47	2.87	2.65-3.11	2.87e-146	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	334	2.5e-245	0.0408759	0.0813		0.622	0.615-0.63	OR	3.69	3.16-4.31	3.69	3.16-4.31	2.94	2.6-3.32	2.94	2.6-3.32	2.49	2.28-2.71	2.49	2.28-2.71	2.26	2.11-2.42	2.26	2.11-2.42	2.09	1.98-2.21	2.09	1.98-2.21	1.51	1.38-1.66	5.03e-19	1.96	1.8-2.14	3.8e-52	3.12	2.87-3.38	2.94e-164	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	10	1.8e-36	0.0048623	0.0826		0.542	0.534-0.55	OR	1.49	1.2-1.86	1.49	1.2-1.86	1.43	1.22-1.68	1.43	1.22-1.68	1.42	1.28-1.57	1.42	1.28-1.57	1.32	1.22-1.42	1.32	1.22-1.42	1.33	1.25-1.4	1.33	1.25-1.4	1.16	1.07-1.25	0.000277	1.31	1.21-1.42	5.25e-12	1.53	1.42-1.65	3.22e-29	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	86	1.1e-157	0.027687	0.0819		0.597	0.59-0.604	OR	2.68	2.25-3.19	2.68	2.25-3.19	2.3	2.01-2.62	2.3	2.01-2.62	2.06	1.88-2.25	2.06	1.88-2.25	1.98	1.85-2.13	1.98	1.85-2.13	1.8	1.71-1.9	1.8	1.71-1.9	1.22	1.11-1.32	9.65e-06	1.66	1.53-1.8	1.83e-34	2.33	2.16-2.52	2.18e-102	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-overall-brca-p-5e-08-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-p-5e-08-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608	P_5e-08	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	GWAS Hits	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	110	3.8e-170	0.0299344	0.0818		0.601	0.594-0.608	OR	2.5	2.09-2.99	2.5	2.09-2.99	2.38	2.09-2.72	2.38	2.09-2.72	2.12	1.94-2.32	2.12	1.94-2.32	2.04	1.9-2.18	2.04	1.9-2.18	1.87	1.77-1.98	1.87	1.77-1.98	1.27	1.17-1.39	5.04e-08	1.72	1.59-1.87	3.06e-38	2.49	2.3-2.69	2.23e-116	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-pt-ukb-20200608	prsweb-phecode174-1-gwas-catalog-r2019-05-03-x174-1-pt-ukb-20200608	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608	174.1	Breast cancer;Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Breast cancer in BRCA2 mutation carriers	Binary	136 unique SNPs	UKB	UK Biobank	P&T	GWAS Catalog (2019-05-03)	17529967;17529973;17529974;18326623;19330027;19330030;20453838;20852631;20872241;21263130;21424380;23354978;23535729;23535733;23544012;23544013;25751625;29058716;29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=17529967+17529973+17529974+18326623+19330027+19330030+20453838+20852631+20872241+21263130+21424380+23354978+23535729+23535733+23544012+23544013+25751625+29058716+29059683	79	5.7e-155	0.0279805	0.0819		0.598	0.59-0.605	OR	2.68	2.25-3.18	2.68	2.25-3.18	2.3	2.01-2.62	2.3	2.01-2.62	2.09	1.91-2.28	2.09	1.91-2.28	1.93	1.8-2.07	1.93	1.8-2.07	1.83	1.74-1.93	1.83	1.74-1.93	1.4	1.29-1.53	1.51e-14	1.69	1.56-1.84	3.07e-35	2.5	2.31-2.71	8.13e-116	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=2.51e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-pt-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	49	8.9e-63	0.00912193	0.0824		0.559	0.551-0.566	OR	2.03	1.67-2.46	2.03	1.67-2.46	1.98	1.72-2.28	1.98	1.72-2.28	1.63	1.48-1.8	1.63	1.48-1.8	1.59	1.47-1.71	1.59	1.47-1.71	1.45	1.38-1.54	1.45	1.38-1.54	1.26	1.16-1.36	2.24e-08	1.37	1.27-1.49	3.23e-15	1.76	1.63-1.9	7.25e-49	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-pt-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	747	1.1e-235	0.0394014	0.0814		0.621	0.614-0.628	OR	3.36	2.87-3.95	3.36	2.87-3.95	2.9	2.56-3.27	2.9	2.56-3.27	2.46	2.26-2.68	2.46	2.26-2.68	2.26	2.11-2.42	2.26	2.11-2.42	2.08	1.97-2.2	2.08	1.97-2.2	1.34	1.23-1.47	1.26e-10	1.88	1.72-2.04	1.17e-47	2.93	2.71-3.17	4.27e-153	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=2.51e-05	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-pt-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1682	2.5e-270	0.0454844	0.0811		0.63	0.623-0.637	OR	3.32	2.83-3.9	3.32	2.83-3.9	2.96	2.62-3.34	2.96	2.62-3.34	2.57	2.36-2.8	2.57	2.36-2.8	2.44	2.29-2.61	2.44	2.29-2.61	2.18	2.07-2.3	2.18	2.07-2.3	1.58	1.44-1.74	1.2e-22	2.01	1.84-2.2	1.95e-54	3.34	3.08-3.63	5.69e-180	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=1e-04	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-pt-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	14	2.2e-44	0.00581917	0.0825		0.547	0.54-0.555	OR	1.73	1.41-2.13	1.73	1.41-2.13	1.63	1.4-1.89	1.63	1.4-1.89	1.51	1.36-1.67	1.51	1.36-1.67	1.39	1.29-1.5	1.39	1.29-1.5	1.38	1.3-1.46	1.38	1.3-1.46	1.2	1.1-1.29	1.11e-05	1.35	1.25-1.46	6.02e-14	1.63	1.51-1.76	3.48e-37	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=3.16e-07	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-pt-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	174	3.6e-169	0.0287248	0.0818		0.6	0.593-0.608	OR	2.92	2.47-3.46	2.92	2.47-3.46	2.4	2.11-2.73	2.4	2.11-2.73	2.03	1.86-2.23	2.03	1.86-2.23	1.98	1.85-2.13	1.98	1.85-2.13	1.93	1.82-2.03	1.93	1.82-2.03	1.35	1.24-1.48	8.26e-12	1.64	1.51-1.78	3.22e-31	2.57	2.37-2.77	1.54e-123	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=3.98e-06	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-overall-brca-pt-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-pt-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608	P&T	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	P&T	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	85	9.6e-173	0.0305568	0.0818		0.602	0.594-0.609	OR	2.78	2.34-3.3	2.78	2.34-3.3	2.45	2.15-2.78	2.45	2.15-2.78	2.09	1.91-2.28	2.09	1.91-2.28	2.03	1.89-2.17	2.03	1.89-2.17	1.88	1.78-1.99	1.88	1.78-1.99	1.29	1.18-1.4	1.77e-08	1.75	1.61-1.9	6.5e-40	2.53	2.34-2.74	8.44e-120	True	False	False	True	Female	6242	62289	GRCh37/hg19	P<=1e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1120410	6e-101	0.0127814	0.0822		0.579	0.572-0.586	OR	2.34	1.95-2.82	2.34	1.95-2.82	2.13	1.86-2.45	2.13	1.86-2.45	1.84	1.67-2.02	1.84	1.67-2.02	1.72	1.6-1.85	1.72	1.6-1.85	1.65	1.56-1.74	1.65	1.56-1.74	1.25	1.15-1.35	2.15e-07	1.49	1.37-1.61	4.35e-22	2.05	1.9-2.22	1.45e-76	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1120410	1.1225369292536e-308	0.0496967	0.0809		0.64	0.634-0.647	OR	3.64	3.12-4.25	3.64	3.12-4.25	3.32	2.96-3.73	3.32	2.96-3.73	2.82	2.6-3.07	2.82	2.6-3.07	2.52	2.36-2.69	2.52	2.36-2.69	2.32	2.2-2.44	2.32	2.2-2.44	1.62	1.47-1.78	2.11e-23	2.21	2.02-2.41	2.6e-66	3.72	3.42-4.05	1.86e-203	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1120410	2.1e-364	0.0559815	0.0805		0.652	0.645-0.658	OR	4.38	3.79-5.07	4.38	3.79-5.07	3.53	3.15-3.95	3.53	3.15-3.95	3.08	2.84-3.33	3.08	2.84-3.33	2.86	2.68-3.04	2.86	2.68-3.04	2.42	2.29-2.55	2.42	2.29-2.55	1.66	1.51-1.83	1.68e-24	2.37	2.16-2.6	7.59e-76	4.05	3.71-4.41	5.72e-221	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1116435	2.1e-38	0.00307076	0.0826		0.549	0.542-0.556	OR	1.82	1.48-2.22	1.82	1.48-2.22	1.66	1.43-1.93	1.66	1.43-1.93	1.43	1.29-1.58	1.43	1.29-1.58	1.43	1.32-1.54	1.43	1.32-1.54	1.34	1.27-1.42	1.34	1.27-1.42	1.21	1.12-1.31	2.41e-06	1.28	1.18-1.38	8.44e-10	1.56	1.45-1.68	2.23e-31	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1116495	3.3e-205	0.0308854	0.0816		0.614	0.607-0.62	OR	2.98	2.52-3.52	2.98	2.52-3.52	2.68	2.37-3.04	2.68	2.37-3.04	2.3	2.11-2.51	2.3	2.11-2.51	2.11	1.97-2.26	2.11	1.97-2.26	1.96	1.86-2.07	1.96	1.86-2.07	1.4	1.28-1.53	2.28e-13	1.89	1.74-2.06	1.93e-49	2.8	2.58-3.03	8.95e-140	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-overall-brca-prs-cs-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-prs-cs-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608	PRS-CS	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	PRS-CS	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	1116546	5.8e-243	0.0371435	0.0813		0.623	0.615-0.63	OR	3.54	3.02-4.14	3.54	3.02-4.14	3.09	2.74-3.48	3.09	2.74-3.48	2.52	2.31-2.74	2.52	2.31-2.74	2.31	2.16-2.47	2.31	2.16-2.47	2.07	1.96-2.18	2.07	1.96-2.18	1.5	1.37-1.64	3.16e-18	1.95	1.79-2.13	4.77e-52	3.07	2.83-3.33	1.03e-160	True	False	False	True	Female	6242	62289	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-negative-brca-lassosum-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-negative-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	41744	3e-98	0.0129908	0.0822		0.576	0.568-0.583	OR	2.25	1.86-2.71	2.25	1.86-2.71	2.1	1.83-2.41	2.1	1.83-2.41	1.92	1.75-2.11	1.92	1.75-2.11	1.69	1.58-1.82	1.69	1.58-1.82	1.59	1.5-1.68	1.59	1.5-1.68	1.28	1.18-1.39	7.35e-09	1.54	1.42-1.67	6.88e-26	2.02	1.87-2.18	3.72e-72	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.9;Lambda=0.006952	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-er-positive-brca-lassosum-ukb-20200608	prsweb-phecode174-1-onco-icogs-er-positive-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	148560	1.4e-274	0.044924	0.0811		0.631	0.624-0.638	OR	3.86	3.31-4.5	3.86	3.31-4.5	3.22	2.87-3.63	3.22	2.87-3.63	2.67	2.45-2.9	2.67	2.45-2.9	2.46	2.3-2.62	2.46	2.3-2.62	2.2	2.09-2.32	2.2	2.09-2.32	1.56	1.43-1.72	2.04e-21	2.04	1.86-2.22	5.17e-56	3.37	3.1-3.66	4.89e-182	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.9;Lambda=0.008859	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-onco-icogs-overall-brca-lassosum-ukb-20200608	prsweb-phecode174-1-onco-icogs-overall-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	286144	2.91e-325	0.0514329	0.0807		0.643	0.637-0.65	OR	4.02	3.46-4.67	4.02	3.46-4.67	3.44	3.07-3.86	3.44	3.07-3.86	2.86	2.63-3.1	2.86	2.63-3.1	2.7	2.53-2.88	2.7	2.53-2.88	2.36	2.24-2.49	2.36	2.24-2.49	1.6	1.46-1.76	2.22e-22	2.16	1.98-2.37	7.26e-63	3.75	3.45-4.08	4.69e-207	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.9;Lambda=0.004281	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-negative-brca-lassosum-ukb-20200608	prsweb-phecode174-1-icogs-er-negative-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female]; ER negative	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	2708	9.9e-44	0.00547943	0.0825		0.547	0.54-0.555	OR	1.72	1.4-2.11	1.72	1.4-2.11	1.67	1.44-1.94	1.67	1.44-1.94	1.54	1.39-1.71	1.54	1.39-1.71	1.42	1.31-1.53	1.42	1.31-1.53	1.37	1.3-1.45	1.37	1.3-1.45	1.14	1.05-1.23	0.00156	1.31	1.21-1.41	7.04e-12	1.58	1.47-1.7	2.92e-33	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.9;Lambda=0.008859	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-er-positive-brca-lassosum-ukb-20200608	prsweb-phecode174-1-icogs-er-positive-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female]; ER positive	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	12277	1.3e-194	0.0339124	0.0816		0.608	0.601-0.615	OR	3	2.54-3.54	3	2.54-3.54	2.8	2.47-3.17	2.8	2.47-3.17	2.44	2.24-2.66	2.44	2.24-2.66	2.1	1.96-2.25	2.1	1.96-2.25	1.93	1.83-2.03	1.93	1.83-2.03	1.4	1.28-1.53	5.75e-14	1.8	1.66-1.96	1.23e-42	2.7	2.49-2.92	2.61e-132	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.5;Lambda=0.01129	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08
prsweb-phecode174-1-icogs-overall-brca-lassosum-ukb-20200608	prsweb-phecode174-1-icogs-overall-brca-lassosum-ukb-20200608	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608	Lassosum	PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608	174.1	Breast cancer [female], Overall	Binary	You are free to use make use of this resource in publications. If you do so, please cite Michailidou et al (2017) and please acknowledge the following: The breast cancer genome-wide association analyses were supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the ‘Ministère de l’Économie, de la Science et de l’Innovation du Québec’ through Genome Québec and grant PSR-SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-223175 and H2020 633784 and 634935). All studies and funders are listed in Michailidou et al (2017).	UKB	UK Biobank	lassosum	Michailidou K et al. 2018	29059683	https://www.ncbi.nlm.nih.gov/pubmed/?term=29059683	7118	4.8e-220	0.037025	0.0814		0.615	0.607-0.622	OR	3.55	3.04-4.16	3.55	3.04-4.16	2.99	2.65-3.37	2.99	2.65-3.37	2.54	2.34-2.77	2.54	2.34-2.77	2.23	2.08-2.38	2.23	2.08-2.38	1.98	1.88-2.09	1.98	1.88-2.09	1.47	1.35-1.61	2.16e-17	1.93	1.77-2.1	5.14e-51	2.9	2.68-3.15	2.33e-147	True	False	False	True	Female	6242	62289	GRCh37/hg19	s=0.5;Lambda=0.006952	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608/exclusion.tsv	2020-06-08